Cargando…

Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models

Butyrophilin 3A1 (BTN3A1), a major histocompatibility complex‐associated gene that encodes a membrane protein with two extracellular immunoglobulin domains and an intracellular B30.2 domain, is critical in T‐cell activation and adaptive immune response. Here, the expression of BTN3A1 in cancers was...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Fan, Zhang, Chen, Guo, Hua, Gao, San‐Hui, Yang, Fu‐Ying, Zhou, Guang‐Biao, Wang, Gui‐Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409294/
https://www.ncbi.nlm.nih.gov/pubmed/34293829
http://dx.doi.org/10.1002/2211-5463.13256
_version_ 1783746969716391936
author Liang, Fan
Zhang, Chen
Guo, Hua
Gao, San‐Hui
Yang, Fu‐Ying
Zhou, Guang‐Biao
Wang, Gui‐Zhen
author_facet Liang, Fan
Zhang, Chen
Guo, Hua
Gao, San‐Hui
Yang, Fu‐Ying
Zhou, Guang‐Biao
Wang, Gui‐Zhen
author_sort Liang, Fan
collection PubMed
description Butyrophilin 3A1 (BTN3A1), a major histocompatibility complex‐associated gene that encodes a membrane protein with two extracellular immunoglobulin domains and an intracellular B30.2 domain, is critical in T‐cell activation and adaptive immune response. Here, the expression of BTN3A1 in cancers was analyzed in eight databases comprising 86 733 patients of 33 cancers, and the findings were validated in patient samples and cell models. We showed that BTN3A1 was expressed in most cancers, and its expression level was strongly correlated with clinical outcome of 13 cancers. Mutations of BTN3A1 were detected, and the mutations were distributed throughout the entire gene. Gene set enrichment analysis showed that BTN3A1 co‐expression genes and interacting proteins were enriched in immune regulation‐related pathways. BTN3A1 was associated with tumor‐infiltrating immune cells and was co‐expressed with multiple immune checkpoints in patients with breast cancer (BRCA) and non‐small cell lung cancer (NSCLC). We reported that BTN3A1 was downregulated in 46 of 65 (70.8%) NSCLCs, and its expression level was inversely associated with clinical outcome of the patients. BTN3A1 in tumor samples was lower than in counterpart normal tissues in 31 of 38 (81.6%) BRCAs. Bioinformatics analyses showed that BTN3A1 could be a target gene of transcription factor Spi‐1 proto‐oncogene (SPI1), and our ‘wet’ experiments showed that ectopic expression of SPI1 upregulated, whereas silencing of SPI1 downregulated, BTN3A1 expression in cells. These results suggest that BTN3A1 may function as a tumor suppressor and may serve as a potential prognostic biomarker in NSCLCs and BRCAs.
format Online
Article
Text
id pubmed-8409294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84092942021-09-03 Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models Liang, Fan Zhang, Chen Guo, Hua Gao, San‐Hui Yang, Fu‐Ying Zhou, Guang‐Biao Wang, Gui‐Zhen FEBS Open Bio Research Articles Butyrophilin 3A1 (BTN3A1), a major histocompatibility complex‐associated gene that encodes a membrane protein with two extracellular immunoglobulin domains and an intracellular B30.2 domain, is critical in T‐cell activation and adaptive immune response. Here, the expression of BTN3A1 in cancers was analyzed in eight databases comprising 86 733 patients of 33 cancers, and the findings were validated in patient samples and cell models. We showed that BTN3A1 was expressed in most cancers, and its expression level was strongly correlated with clinical outcome of 13 cancers. Mutations of BTN3A1 were detected, and the mutations were distributed throughout the entire gene. Gene set enrichment analysis showed that BTN3A1 co‐expression genes and interacting proteins were enriched in immune regulation‐related pathways. BTN3A1 was associated with tumor‐infiltrating immune cells and was co‐expressed with multiple immune checkpoints in patients with breast cancer (BRCA) and non‐small cell lung cancer (NSCLC). We reported that BTN3A1 was downregulated in 46 of 65 (70.8%) NSCLCs, and its expression level was inversely associated with clinical outcome of the patients. BTN3A1 in tumor samples was lower than in counterpart normal tissues in 31 of 38 (81.6%) BRCAs. Bioinformatics analyses showed that BTN3A1 could be a target gene of transcription factor Spi‐1 proto‐oncogene (SPI1), and our ‘wet’ experiments showed that ectopic expression of SPI1 upregulated, whereas silencing of SPI1 downregulated, BTN3A1 expression in cells. These results suggest that BTN3A1 may function as a tumor suppressor and may serve as a potential prognostic biomarker in NSCLCs and BRCAs. John Wiley and Sons Inc. 2021-08-04 /pmc/articles/PMC8409294/ /pubmed/34293829 http://dx.doi.org/10.1002/2211-5463.13256 Text en © 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Liang, Fan
Zhang, Chen
Guo, Hua
Gao, San‐Hui
Yang, Fu‐Ying
Zhou, Guang‐Biao
Wang, Gui‐Zhen
Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models
title Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models
title_full Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models
title_fullStr Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models
title_full_unstemmed Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models
title_short Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models
title_sort comprehensive analysis of btn3a1 in cancers: mining of omics data and validation in patient samples and cellular models
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409294/
https://www.ncbi.nlm.nih.gov/pubmed/34293829
http://dx.doi.org/10.1002/2211-5463.13256
work_keys_str_mv AT liangfan comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels
AT zhangchen comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels
AT guohua comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels
AT gaosanhui comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels
AT yangfuying comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels
AT zhouguangbiao comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels
AT wangguizhen comprehensiveanalysisofbtn3a1incancersminingofomicsdataandvalidationinpatientsamplesandcellularmodels